Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 55

1.

Platinum exposure and cause-specific mortality among patients with testicular cancer.

Groot HJ, van Leeuwen FE, Lubberts S, Horenblas S, de Wit R, Witjes JA, Groenewegen G, Poortmans PM, Hulshof MCCM, Meijer OWM, de Jong IJ, van den Berg HA, Smilde TJ, Vanneste BGL, Aarts MJB, Jóźwiak K, van den Belt-Dusebout AW, Gietema JA, Schaapveld M.

Cancer. 2020 Feb 1;126(3):628-639. doi: 10.1002/cncr.32538. Epub 2019 Nov 15.

2.

Risk of diabetes after para-aortic radiation for testicular cancer.

Groot HJ, Gietema JA, Aleman BMP, Incrocci L, de Wit R, Witjes JA, Groenewegen G, de Brouwer P, Meijer OWM, Hulshof MCCM, van den Berg HA, Smilde TJ, Vanneste BGL, Aarts MJ, van den Bergh ACM, Kerst JM, van den Belt-Dusebout AW, Lubberts S, Jóźwiak K, Horenblas S, van Leeuwen FE, Schaapveld M.

Br J Cancer. 2018 Oct;119(7):901-907. doi: 10.1038/s41416-018-0248-x. Epub 2018 Oct 9.

3.

Risk of Solid Cancer After Treatment of Testicular Germ Cell Cancer in the Platinum Era.

Groot HJ, Lubberts S, de Wit R, Witjes JA, Kerst JM, de Jong IJ, Groenewegen G, van den Eertwegh AJM, Poortmans PM, Klümpen HJ, van den Berg HA, Smilde TJ, Vanneste BGL, Aarts MJ, Incrocci L, van den Bergh ACM, Jóźwiak K, van den Belt-Dusebout AW, Horenblas S, Gietema JA, van Leeuwen FE, Schaapveld M.

J Clin Oncol. 2018 Aug 20;36(24):2504-2513. doi: 10.1200/JCO.2017.77.4174. Epub 2018 Jul 10.

PMID:
29989856
4.

Real-world use, safety, and survival of ipilimumab in metastatic cutaneous melanoma in The Netherlands.

Jochems A, Leeneman B, Franken MG, Schouwenburg MG, Aarts MJB, van Akkooi ACJ, van den Berkmortel FWPJ, van den Eertwegh AJM, Groenewegen G, de Groot JWB, Haanen JBAG, Hospers GAP, Kapiteijn E, Koornstra RH, Kruit WHJ, Louwman MWJ, Piersma D, van Rijn RS, Ten Tije AJ, Vreugdenhil G, Wouters MWJM, Uyl-de Groot CA, van der Hoeven KJM.

Anticancer Drugs. 2018 Jul;29(6):572-578. doi: 10.1097/CAD.0000000000000629.

PMID:
29659371
5.

Dutch Melanoma Treatment Registry: Quality assurance in the care of patients with metastatic melanoma in the Netherlands.

Jochems A, Schouwenburg MG, Leeneman B, Franken MG, van den Eertwegh AJ, Haanen JB, Gelderblom H, Uyl-de Groot CA, Aarts MJ, van den Berkmortel FW, Blokx WA, Cardous-Ubbink MC, Groenewegen G, de Groot JW, Hospers GA, Kapiteijn E, Koornstra RH, Kruit WH, Louwman MW, Piersma D, van Rijn RS, Ten Tije AJ, Vreugdenhil G, Wouters MW, van der Hoeven JJ.

Eur J Cancer. 2017 Feb;72:156-165. doi: 10.1016/j.ejca.2016.11.021. Epub 2016 Dec 25.

PMID:
28030784
6.

Alternating Treatment With Pazopanib and Everolimus vs Continuous Pazopanib to Delay Disease Progression in Patients With Metastatic Clear Cell Renal Cell Cancer: The ROPETAR Randomized Clinical Trial.

Cirkel GA, Hamberg P, Sleijfer S, Loosveld OJL, Dercksen MW, Los M, Polee MB, van den Berkmortel F, Aarts MJ, Beerepoot LV, Groenewegen G, Lolkema MP, Tascilar M, Portielje JEA, Peters FPJ, Klümpen HJ, van der Noort V, Haanen JBAG, Voest EE; Dutch WIN-O Consortium.

JAMA Oncol. 2017 Apr 1;3(4):501-508. doi: 10.1001/jamaoncol.2016.5202.

PMID:
27918762
7.

Targeting the endothelin axis with atrasentan, in combination with IFN-alpha, in metastatic renal cell carcinoma.

Groenewegen G, Walraven M, Vermaat J, de Gast B, Witteveen E, Giles R, Haanen J, Voest E.

Br J Cancer. 2012 Jan 17;106(2):284-9. doi: 10.1038/bjc.2011.515. Epub 2012 Jan 3.

8.

Phase 1/2 study of atrasentan combined with pegylated liposomal doxorubicin in platinum-resistant recurrent ovarian cancer.

Witteveen PO, van der Mijn KJ, Los M, Kronemeijer RH, Groenewegen G, Voest EE.

Neoplasia. 2010 Nov;12(11):941-5.

9.

Impact of integration of clinical and outpatient units on cancer patient satisfaction.

Wessels H, de Graeff A, Groenewegen G, Wynia K, de Heus M, Vos JB, Tjia P, Kruitwagen CL, Teunissen SC, Voest EE.

Int J Qual Health Care. 2010 Oct;22(5):358-64. doi: 10.1093/intqhc/mzq041. Epub 2010 Aug 3.

PMID:
20682634
10.

Two-protein signature of novel serological markers apolipoprotein-A2 and serum amyloid alpha predicts prognosis in patients with metastatic renal cell cancer and improves the currently used prognostic survival models.

Vermaat JS, van der Tweel I, Mehra N, Sleijfer S, Haanen JB, Roodhart JM, Engwegen JY, Korse CM, Langenberg MH, Kruit W, Groenewegen G, Giles RH, Schellens JH, Beijnen JH, Voest EE.

Ann Oncol. 2010 Jul;21(7):1472-81. doi: 10.1093/annonc/mdp559. Epub 2009 Dec 18.

11.

A comparison of six software packages for evaluation of solid lung nodules using semi-automated volumetry: what is the minimum increase in size to detect growth in repeated CT examinations.

de Hoop B, Gietema H, van Ginneken B, Zanen P, Groenewegen G, Prokop M.

Eur Radiol. 2009 Apr;19(4):800-8. doi: 10.1007/s00330-008-1229-x. Epub 2008 Nov 19.

PMID:
19018537
12.

[Angiogenesis inhibitors for the systemic treatment of metastatic renal cell carcinoma: sunitinib, sorafenib, bevacizumab and temsirolimus].

de Mulder PH, Haanen JB, Sleijfer S, Kruit WH, Gietema JA, Richel DJ, Groenewegen G, Voest EE, van den Eertwegh AJ, Osanto S, Jansen RL, Mulders PF.

Ned Tijdschr Geneeskd. 2008 Feb 16;152(7):371-5. Review. Dutch.

PMID:
18380383
13.

Pulmonary nodules: Interscan variability of semiautomated volume measurements with multisection CT-- influence of inspiration level, nodule size, and segmentation performance.

Gietema HA, Schaefer-Prokop CM, Mali WP, Groenewegen G, Prokop M.

Radiology. 2007 Dec;245(3):888-94. Epub 2007 Oct 8.

PMID:
17923508
14.

Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial.

Eggermont AM, Suciu S, MacKie R, Ruka W, Testori A, Kruit W, Punt CJ, Delauney M, Sales F, Groenewegen G, Ruiter DJ, Jagiello I, Stoitchkov K, Keilholz U, Lienard D; EORTC Melanoma Group.

Lancet. 2005 Oct 1;366(9492):1189-96.

PMID:
16198768
15.

A phase I/II and pharmacokinetic study of irinotecan in combination with capecitabine as first-line therapy for advanced colorectal cancer.

Rea DW, Nortier JW, Ten Bokkel Huinink WW, Falk S, Richel DJ, Maughan T, Groenewegen G, Smit JM, Steven N, Bakker JM, Semiond D, Kerr DJ, Punt CJ.

Ann Oncol. 2005 Jul;16(7):1123-32. Epub 2005 Jun 6.

16.

Phase I investigation of recombinant anti-human vascular endothelial growth factor antibody in patients with advanced cancer.

Jayson GC, Mulatero C, Ranson M, Zweit J, Jackson A, Broughton L, Wagstaff J, Hakansson L, Groenewegen G, Lawrance J, Tang M, Wauk L, Levitt D, Marreaud S, Lehmann FF, Herold M, Zwierzina H; European Organisation for Research and Treatment of Cancer (EORTC).

Eur J Cancer. 2005 Mar;41(4):555-63. Epub 2005 Jan 22.

PMID:
15737560
17.

Phase I and pharmacokinetic study of the combination of topotecan and ifosfamide administered intravenously every 3 weeks.

Kerbusch T, Groenewegen G, Mathôt RA, Herben VM, ten Bokkel Huinink WW, Swart M, Ambaum B, Rosing H, Jansen S, Voest EE, Beijnen JH, Schellens JH.

Br J Cancer. 2004 Jun 14;90(12):2268-77.

18.

Phase I clinical trial of the bispecific antibody MDX-H210 (anti-FcgammaRI x anti-HER-2/neu) in combination with Filgrastim (G-CSF) for treatment of advanced breast cancer.

Repp R, van Ojik HH, Valerius T, Groenewegen G, Wieland G, Oetzel C, Stockmeyer B, Becker W, Eisenhut M, Steininger H, Deo YM, Blijham GH, Kalden JR, van de Winkel JG, Gramatzki M.

Br J Cancer. 2003 Dec 15;89(12):2234-43.

19.

Recombinant human angiostatin by twice-daily subcutaneous injection in advanced cancer: a pharmacokinetic and long-term safety study.

Beerepoot LV, Witteveen EO, Groenewegen G, Fogler WE, Sim BK, Sidor C, Zonnenberg BA, Schramel F, Gebbink MF, Voest EE.

Clin Cancer Res. 2003 Sep 15;9(11):4025-33.

20.

The angiogenic factor bFGF impairs leukocyte adhesion and rolling under flow conditions.

Griffioen AW, Relou IA, Gallardo Torres HI, Damen CA, Martinotti S, De Graaf JC, Zwaginga JJ, Groenewegen G.

Angiogenesis. 1998;2(3):235-43.

PMID:
14517463
21.

Phase I dose-escalation study of the safety and pharmacokinetics of atrasentan: an endothelin receptor antagonist for refractory prostate cancer.

Zonnenberg BA, Groenewegen G, Janus TJ, Leahy TW, Humerickhouse RA, Isaacson JD, Carr RA, Voest E.

Clin Cancer Res. 2003 Aug 1;9(8):2965-72.

22.

Immunotherapy with concurrent subcutaneous GM-CSF, low-dose IL-2 and IFN-alpha in patients with progressive metastatic renal cell carcinoma.

Verra N, Jansen R, Groenewegen G, Mallo H, Kersten MJ, Bex A, Vyth-Dreese FA, Sein J, van de Kasteele W, Nooijen WJ, de Waal M, Horenblas S, de Gast GC.

Br J Cancer. 2003 May 6;88(9):1346-51.

24.

Molecular imaging and biological evaluation of HuMV833 anti-VEGF antibody: implications for trial design of antiangiogenic antibodies.

Jayson GC, Zweit J, Jackson A, Mulatero C, Julyan P, Ranson M, Broughton L, Wagstaff J, Hakannson L, Groenewegen G, Bailey J, Smith N, Hastings D, Lawrance J, Haroon H, Ward T, McGown AT, Tang M, Levitt D, Marreaud S, Lehmann FF, Herold M, Zwierzina H; European Organisation for Research and Treatment of Cancer Biological Therapeutic Development Group.

J Natl Cancer Inst. 2002 Oct 2;94(19):1484-93.

PMID:
12359857
25.

Phase I and pharmacokinetic study of SPI-77, a liposomal encapsulated dosage form of cisplatin.

Meerum Terwogt JM, Groenewegen G, Pluim D, Maliepaard M, Tibben MM, Huisman A, ten Bokkel Huinink WW, Schot M, Welbank H, Voest EE, Beijnen JH, Schellens JM.

Cancer Chemother Pharmacol. 2002 Mar;49(3):201-10. Epub 2002 Jan 22.

PMID:
11935212
26.

[Interferon for adjuvant therapy in melanoma; although approved, not indicated].

Groenewegen G, Osanto S, van der Rhee HJ, Punt CJ.

Ned Tijdschr Geneeskd. 2000 Nov 4;144(45):2160-2. Review. Dutch.

PMID:
11086492
27.
28.

GM-CSF can cause T cell activation; results of sequential chemo-immunotherapy.

Groenewegen G, de Gast GC.

Eur J Cancer. 1999 Aug;35 Suppl 3:S23-4. No abstract available.

PMID:
10645217
29.

Angiogenesis inhibitors overcome tumor induced endothelial cell anergy.

Griffioen AW, Damen CA, Mayo KH, Barendsz-Janson AF, Martinotti S, Blijham GH, Groenewegen G.

Int J Cancer. 1999 Jan 18;80(2):315-9.

30.

Effect of culture conditions on endothelial cell growth and responsiveness.

Relou IA, Damen CA, van der Schaft DW, Groenewegen G, Griffioen AW.

Tissue Cell. 1998 Oct;30(5):525-30.

PMID:
9839475
31.

Endothelial CD34 is suppressed in human malignancies: role of angiogenic factors.

Hellwig SM, Damen CA, van Adrichem NP, Blijham GH, Groenewegen G, Griffioen AW.

Cancer Lett. 1997 Dec 9;120(2):203-11.

PMID:
9461038
32.

Clinical evaluation of the bispecific antibody MDX-H210 (anti-Fc gamma RI x anti-HER-2/neu) in combination with granulocyte-colony-stimulating factor (filgrastim) for treatment of advanced breast cancer.

van Ojik HH, Repp R, Groenewegen G, Valerius T, van de Winkel JG.

Cancer Immunol Immunother. 1997 Nov-Dec;45(3-4):207-9. No abstract available.

PMID:
9435875
33.

CD44 is involved in tumor angiogenesis; an activation antigen on human endothelial cells.

Griffioen AW, Coenen MJ, Damen CA, Hellwig SM, van Weering DH, Vooys W, Blijham GH, Groenewegen G.

Blood. 1997 Aug 1;90(3):1150-9.

PMID:
9242547
34.

Tumor angiogenesis is accompanied by a decreased inflammatory response of tumor-associated endothelium.

Griffioen AW, Damen CA, Blijham GH, Groenewegen G.

Blood. 1996 Jul 15;88(2):667-73.

PMID:
8695814
35.

Endothelial intercellular adhesion molecule-1 expression is suppressed in human malignancies: the role of angiogenic factors.

Griffioen AW, Damen CA, Martinotti S, Blijham GH, Groenewegen G.

Cancer Res. 1996 Mar 1;56(5):1111-17.

36.

Endoglin/CD 105 may not be an optimal tumor endothelial treatment target.

Griffioen AW, Damen CA, Blijham GH, Groenewegen G.

Breast Cancer Res Treat. 1996;39(2):239-42. No abstract available.

PMID:
8872333
37.

Limiting dilution assays. Experimental design and statistical analysis.

Strijbosch LW, Buurman WA, Does RJ, Zinken PH, Groenewegen G.

J Immunol Methods. 1987 Feb 26;97(1):133-40.

PMID:
3819436
38.

A new lymphokine different from interferon-gamma induces major histocompatibility complex class II antigen expression.

Groenewegen G, Buurman WA, de Ley M, Kootstra G.

Transplant Proc. 1987 Feb;19(1 Pt 1):190-1. No abstract available.

PMID:
3152685
39.
40.

Alloantigen presentation by canine endothelial cells. Presentation of autologous alloantigens in vitro.

Groenewegen G, Buurman WA, Jeunhomme GM.

Transplantation. 1986 Jun;41(6):751-4.

PMID:
2940738
41.

Cyclosporin A inhibits IL 2-driven proliferation of human alloactivated T cells.

Buurman WA, Ruers TJ, Daemen IA, van der Linden CJ, Groenewegen G.

J Immunol. 1986 Jun 1;136(11):4035-9.

PMID:
2939138
42.

Canine MHC-class II antigens on B and T lymphocytes.

Doveren RF, van der Linden CJ, Spronken EE, Groenewegen G, Buurman WA.

Tissue Antigens. 1986 Feb;27(2):87-98.

PMID:
3518148
43.

Lymphokines induce changes in morphology and enhance motility of endothelial cells.

Groenewegen G, Buurman WA, van der Linden CJ.

Clin Immunol Immunopathol. 1985 Sep;36(3):378-85.

PMID:
4017294
44.

Lymphokine dependence of in vivo expression of MHC class II antigens by endothelium.

Groenewegen G, Buurman WA, van der Linden CJ.

Nature. 1985 Jul 25-31;316(6026):361-3.

PMID:
3927172
45.

Effect of cyclosporine on MHC class II antigen expression on arterial and venous endothelium in vitro.

Groenewegen G, Buurman WA, Jeunhomme GM, van der Linden CJ.

Transplantation. 1985 Jul;40(1):21-5.

PMID:
3160142
46.

Cell-mediated cytotoxicity patterns of cloned cytotoxic T lymphocytes. Cytotoxicity directed against canine lymphoblasts, monocytes, and endothelial cells.

Groenewegen G, Buurman WA, van der Linden CJ, Jeunhomme GM, Kootstra G.

Transplantation. 1985 Jun;39(6):657-60.

PMID:
2408367
47.

Class II antigens on canine T lymphocytes.

Doveren RF, Buurman WA, Schutte B, Groenewegen G, van der Linden CJ.

Tissue Antigens. 1985 May;25(5):255-65.

PMID:
2411015
48.

Influence of a skin allograft on frequencies of CTL precursor in peripheral blood of the dog.

Buurman WA, Groenewegen G, van der Linden CJ, Daemen AJ, Doveren R, Kootstra G.

Transplantation. 1984 Aug;38(2):175-8.

PMID:
6380043
49.

Cell-mediated cytotoxicity toward class I and class II antigens on canine T and B lymphoblasts.

Buurman WA, van der Linden CJ, Daemen AJ, Groenewegen G, Doveren RF, Kootstra G.

Tissue Antigens. 1984 Jul;24(1):48-57.

PMID:
6333088
50.

Vascular endothelial cells present alloantigens to unprimed lymphocytes.

Groenewegen G, Buurman WA.

Scand J Immunol. 1984 Mar;19(3):269-73.

PMID:
6231718

Supplemental Content

Loading ...
Support Center